Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT03221634Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by Merck & Co.. Planned start Aug 2017; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03221634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221634.